Iovance Biotherapeutics (IOVA) Q1 2025 earnings summary

Executive summary

• AMTAGVI (lifileucel) became the first FDA-approved TIL cell therapy for advanced melanoma in February 2024, generating over $210 million in its first U.S. launch year and $49.3 million in Q1 2025, with 300 patient infusions since April 2024.

• Proleukin (aldesleukin), acquired in May 2023, is marketed alongside AMTAGVI and used in its regimen, contributing $5.7–$5.8 million to Q1 2025 revenue.

• Global expansion is underway, with regulatory submissions for AMTAGVI in the UK, EU, Canada, Australia, and Switzerland, and EMA inspections confirming GMP compliance.

• Manufacturing capacity expanded at iCTC and with a CMO, supporting commercial and clinical demand, with annual maintenance at ICTC reducing Q1 capacity by over 50%.

• Pipeline includes registrational trials in frontline advanced melanoma and NSCLC, plus next-generation TIL and cytokine therapies, with updated NSCLC data expected in 2H25.

Financial highlights

• Q1 2025 revenue was $49.3 million, up from $0.7 million in Q1 2024, driven by AMTAGVI and Proleukin sales.

• Net loss for Q1 2025 was $116.2 million ($0.36/share), compared to $113 million ($0.42/share) in Q1 2024.

• Cost of sales rose to $49.7 million, including $15 million in period costs and $5.4 million in non-cash amortization.

• R&D expenses decreased 4% year-over-year to $76.9 million; SG&A expenses increased 40% to $43.9 million.

• Cash, cash equivalents, and investments totaled $366 million as of March 31, 2025, supporting operations into the second half of 2026.

Outlook and guidance

• Full-year 2025 product revenue guidance is $250–$300 million, reflecting over 50% growth, with expectations to surpass 500 AMTAGVI infusions.

• Cash burn for 2025 expected below $300 million, with a focus on spending optimization and a cash runway into 2H26.

• Gross margin projected to exceed 70% in coming years as volume and efficiency improve.

• Peak sales opportunity for AMTAGVI projected at over $1 billion in the U.S. and $2 billion globally.

• Significant revenue growth anticipated for FY26 and beyond, with global regulatory milestones on track.